Physician profile
Robert R Chavez
NPI 1326113069
$144,618.37
in general payments reported to CMS, 2019-2025
11 companies · $35K in 2025
The $35K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $11K · 2021: $13K · 2022: $8,971 · 2023: $17K · 2024: $24K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Travel and Lodging: $6,369 · Food and Beverage: $4,203 · Honoraria: $2,450 · Consulting Fee: $600 · Education: $11.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,810.00 |
| Travel and Lodging | $6,369.31 |
| Food and Beverage | $4,202.57 |
| Honoraria | $2,450.00 |
| Consulting Fee | $600.00 |
| Education | $11.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $133,331.81 | 2019-2025 | Biktarvy, Descovy, Yeztugo |
| Viiv Healthcare Company | $5,824.36 | 2019-2025 | Dovato, Apretude |
| Theratechnologies INC. | $3,226.06 | 2023-2025 | Egrifta, Trogarzo |
| Idorsia Pharmaceuticals US INC | $1,260.00 | 2022 | |
| Emd Serono, INC. | $466.47 | 2023-2025 | Serostim |
| Antares Pharma, INC. | $175.03 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Otsuka America Pharmaceutical, INC. | $117.46 | 2019 | |
| Merck Sharp & Dohme LLC | $110.53 | 2019-2020 | |
| Abbvie INC. | $58.70 | 2024-2025 | |
| Allergan, INC. | $34.79 | 2019 | |
| Halozyme INC | $13.16 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.